About the presentation
"Genetic Protection from Coronary Atherosclerosis"
Cardiovascular disease remains a leading cause of death and disability. The incidence of coronary atherosclerosis is directly related to circulating levels of low density lipoproteins (LDL). Pharmacological reductions in plasma LDL-C levels in adulthood are associated with fewer coronary events in but the effect of life-long reductions in plasma LDL-C is not known. Researchers in Hobbs's lab identified mutations that are associated with a 40 percent reduction in plasma levels of LDL-C and have recently shown that these mutations are associated with a dramatic reduction in coronary atherosclerotic events. These studies suggest that life-long reduction in plasma LDL-C levels magnifies the beneficial effects of LDL-lowering on heart disease.
|
